Introduction and Objective: The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend glucagon-like peptide-1 receptor agonists (GLP1-RA) for type 2 diabetes, but their use in type 1 diabetes (T1D) is limited. This study compared glycemic metrics and adverse events in fasting and non-fasting people with T1D using GLP1-RA during Ramadan.Methods: This prospective observational study included 20 people with T1D who were on a stable GLP1-RA dose and used continuous glucose monitoring (CGM) devices. Among theme, 10 people fasted (mean age±SD: 36.1±8.9 years; HbA1c: 7.7%±1.1%), while 10 did not fast (mean age±SD: 34.6±8.9 years; HbA1c: 8.2%±1.1%). Outcomes measured the percentage of time spent in the target glucose range (3.9-10 mmol/L), hyperglycemic range (>10 mmol/L), hypoglycemic range (<3.9 mmol/L), glucose variability (CV%), glucose management indicator (GMI), and diabetic ketoacidosis (DKA) incidences. All participants received structured education on the safe use of GLP1-RA.Results: The mean fasting duration was 22.7±4.7days (range: 18-29days). There were no significant differences observed between the fasting and non-fasting groups in target range (47.3±19.3% vs. 50.7±19.3%), hyperglycemic range (49.9±19.4% vs. 47.7±20.8%), hypoglycemic range (2.8±2.3% vs. 1.6±2.3%), glycemic variability (36.8±8.4% vs. 36.0±5.0%) and GMI (7.6±0.5% vs. 7.8±0.9%) (all p≥0.22). No severe hypoglycemia, diabetic ketoacidosis (DKA), or hospitalizations were reported in either group during the fasting period.Conclusion: The use of GLP1-RA in people with T1D during fasting appears to be safe and well-tolerated, with no adverse events reported among those who received structured education. However, further clinical trials are required to confirm these findings.
E. Taghadom: None. M. Irshad: None. L.G. Sojan: None. D. Alroudhan: None. J. AlKandari: None. E. Al-Ozairi: None.
Kuwait Foundation for the Advancement of Sciences (KFAS), Kuwait
Source link
Leave a Reply